Burden Fatty Liver Among Acute Ischemic Cerebral Stroke Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Fatty Liver, Acute Ischemic Cerebral Stroke. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
1. Assess frequency of hepatic steatosis among patients in patients with Ischemic stroke without previous risk factors 2. Assess outcomes morbidity and mortality ischemic stroke in correlation with hepatic steatosis .
Detailed description
Fatty liver disease, encompassing both alcoholic and non-alcoholic variants, is a growing health concern worldwide, with prevalence rates soaring in parallel with obesity and diabetes epidemics. The estimated global incidence of NAFLD alone is 47 cases per 1,000 people, with a higher rate observed in males than females. Among adults worldwide, the estimated prevalence of NAFLD is 32%, with a higher prevalence in males (40%) compared to females (26%), making it the most common liver disorder. The hazards of fatty liver disease extend beyond the liver itself .The condition is characterized by the accumulation of excess fat in liver cells, which can progress to more severe liver diseases, such as steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.
Early assessment and diagnosis of liver steatosis are crucial for managing and mitigating the risks associated with FLD. Non-invasive methods, such as elastography combined with the Controlled Attenuation Parameter (CAP) score, have emerged as effective tools for detecting and quantifying liver fat content. These methods offer a less invasive alternative to liver biopsies, providing reliable data to guide clinical decisions.
NAFLD is characterized by a proinflammatory and proatherogenic state that causes vascular inflammation and neurodegeneration, potentially leading to both clinical and subclinical cerebrovascular disease. Increasing epidemiological evidence links NAFLD to a higher risk and greater severity of stroke, independent of other vascular risk factors.Additionally, studies suggest NAFLD is involved in subclinical cerebrovascular diseases, such as carotid atherosclerosis which is characterized by the build-up of plaques in the carotid arteries. Patients with NAFLD exhibited greater carotid atherosclerosis .
Primary outcome measures
- Assess frequency of hepatic steatosis among patients in patients with Ischemic stroke without previous risk factors [Time frame: Baseline]
Secondary outcome measures (1)
- Assess outcomes morbidity and mortality ischemic stroke in correlation with hepatic steatosis . [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Newly diagnosed ischemic cerebral stroke exceeding of window phase without obvious risk factors.
- patients above 18 years.
- patients below 60 years.
Exclusion criteria
- patients have obvious risk factors including: smoking, DM , Hypertension ,renal patients , cardiovascular diseases (AF , valvular disease ,reduced systolic function ,chronic HCV ,HBV).
- patients below 18 years.
- patients above 60 years.
- patients refused to contribute to this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988 Dec;19(12):1497-500. doi: 10.1161/01.str.19.12.1497. PMID 3201508
- DeGraba TJ, Hallenbeck JM, Pettigrew KD, Dutka AJ, Kelly BJ. Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials. Stroke. 1999 Jun;30(6):1208-12. doi: 10.1161/01.str.30.6.1208. PMID 10356101
- Mughal MM, Khan MK, DeMarco JK, Majid A, Shamoun F, Abela GS. Symptomatic and asymptomatic carotid artery plaque. Expert Rev Cardiovasc Ther. 2011 Oct;9(10):1315-30. doi: 10.1586/erc.11.120. PMID 21985544
- Tahmasebpour HR, Buckley AR, Cooperberg PL, Fix CH. Sonographic examination of the carotid arteries. Radiographics. 2005 Nov-Dec;25(6):1561-75. doi: 10.1148/rg.256045013. PMID 16284135
Identifiers
NCT: NCT06628700 · Fatty liver